Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: Experimental study

International Journal of Urology

Volumn 9, Issue 10, 2002, Pages 567-576

  Koshida, K ^a   Yokoyama, K ^a   Mizokami, A ^a   Namiki, M ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cytosine deaminase; Gene therapy; Prostate cancer; Radiation therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; ANTIMETABOLITE; DEAMINASE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; GENE THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; TREATMENT OUTCOME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; CELL CULTURE; EVALUATION; GENETICS; METHODOLOGY; MOUSE MUTANT; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; RADIOTHERAPY;

ANIMALS; ANTIMETABOLITES; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; HUMANS; MALE; MICE; MICE, SCID; MODELS, ANIMAL; NUCLEOSIDE DEAMINASES; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY; TUMOR CELLS, CULTURED;

EID: 0036435242     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00513.x     Document Type: Article

References (28)

1. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 1993; 53: 4619-26.
2. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994; 54: 1503-6.
3. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 1995; 55: 4808-12.
4. Evoy D, Hirschowitz EA, Naama HA et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J. Surg. Res. 1997; 69: 226-31.
5. Kanai F, Lan KH, Shiratori Y et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997; 57: 461-5.
6. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res. 1998; 58: 2588-93.
7. Topf N, Worgall S, Hackett NR, Crystal RG. Regional 'pro-drug' gene therapy: Intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther. 1998; 5: 507-13.
8. Shirakawa T, Gardner TA, Ko SC et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J. Urol. 1999; 162: 949-54.
9. Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, Weichselbaum RR. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 1997; 57: 4205-9.
10. Pederson LC, Buchsbaum DJ, Vickers SM et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 1997; 57: 4325-32.
11. Stackhouse MA, Pederson LC, Grizzle WE et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther. 2000; 7: 1019-26.
12. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J. Natl Cancer Inst. 1996; 88: 1193-203.
13. Sharkey RM, Blumenthal RD, Behr TM et al. Selection of radioimmunoconjugate for the therapy of well-established of micrometastatic colon carcinoma. Int. J. Cancer 1997; 72: 477-85.
14. 131I-labeled monoclonal antibody A33) with chemotherapy (Fluorouracil). Cancer Res. 1997; 57: 2181-6.
15. Kinuya S, Yokoyama K, Tega H et al. Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts. J. Cancer Res. Clin. Oncol. 1999; 125: 630-6.
16. 125I-labelled antibody against prostatic specific antigen. Scand. J. Urol. Nephrol. Suppl. 1988; 110: 149-53.
17. Meyers FJ, Denardo SJ, Macey D, White RD, Unger M. Development of monoclonal antibody imaging of metastatic prostate carcinoma. Prostate 1989; 14: 209-20.
18. Dillman RO, Beauregard J, Ryan KP et al. Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies. NCI Monogr. 1987; 3: 33-6.
19. Koshida K, Endo Y, Kobayashi T et al. Enhanced tumorigenic and metastatic potential of an androgen-sensitive human prostate cancer cell line, LNCaP, by intratesticular inoculation in SCID mice. Int. J. Oncol. 1997; 11: 513-9.
20. Wallace PW, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 1994; 54: 2719-23.
21. 131I-labelled human growth hormone of high specific radioactivity. Biochem. J. 1963; 89: 114-23.
22. Lim DJ, Liu X, Sutkowski DM, Braun EJ, Lee C, Kozlowski JM. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 1993; 22: 109-18.
23. Sato N, Cleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res. 1997; 57: 1584-9.
24. Anello R, Cohen S, Atkinson G, Hall SJ. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to radiation. J. Urol. 2000; 164: 2173-7.
25. Koshida K, Yokoyama K, Uchibayashi T, Yamamoto H, Hirano K, Namiki M. Factors contributing to imaging of xenografts using anti-placental alkaline phosphatase monoclonal antibody. J. Urol. 1997; 157: 1941-5.
26. Hori K, Suzuki M, Abe I, Saito S. Increased tumor tissue pressure in association with the growth of rat tumors. Jpn. J. Cancer Res. 1986; 77: 65-73.
27. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000; 60: 334-41.
28. Koeneman KS, Kao C, Ko SC. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 2000; 18: 102-10.